Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy
NCT04575935Phase 3Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2020
- Primary completion
- Dec 2028
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Disease Free Survival up to 5 years. Started Aug 2020; status: recruiting.
02
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT04575935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04575935.